Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Solifenacin in the treatment of urgency and other symptoms of overactive bladder: Results from a randomized, double-blind, placebo-controlled, rising-dose trial
BJU International, Volume 102, No. 9, Year 2008
Notification
URL copied to clipboard!
Description
OBJECTIVES: To examine the effects of the antimuscarinic agent solifenacin on urinary urgency, using a range of novel and established outcome measures, as urgency is the principal symptom of the overactive bladder syndrome (OAB). PATIENTS AND METHODS: The study (SUNRISE, solifenacin in the treatment of urgency symptoms of OAB in a rising dose, randomized, placebo-controlled, double-blind, efficacy trial) was a randomized, double-blind, 16-week, placebo-controlled, multicentre study of solifenacin 5/10 mg in 863 patients with symptoms of OAB for ≥3 months. The primary efficacy variable was the change from baseline to endpoint in the number of episodes of severe urgency with or without urgency incontinence per 24 h, as measured using the Patient Perception of Intensity of Urgency Scale, grade 3 + 4. Secondary efficacy variables included patient-reported outcomes for bladder condition, urgency bother and treatment satisfaction. A 3-day voiding diary was used to record micturition frequency and episodes of urgency and incontinence. A 7-day diary was used to assess speed of onset of effect. RESULTS: Solifenacin 5/10 mg was significantly more effective than placebo in reducing the mean number of episodes of severe urgency with or without incontinence per 24 h from baseline to endpoint (-2.6 vs -1.8, P < 0.001). There were also statistically significant differences in favour of solifenacin 5/10 mg over placebo for all secondary variables measured at endpoint, including patient-reported outcomes. There was a significant improvement in urgency as early as day 3 of treatment. Treatment-emergent adverse events with solifenacin 5/10 mg were mainly mild or moderate in severity, and only led to discontinuation in 3.6% of patients. CONCLUSION: Solifenacin significantly reduced the number of urgency episodes and the extent of urgency bother, and was well tolerated; it was effective as early as day 3 of treatment. © 2008 The Authors.
Authors & Co-Authors
Cardozo, Linda D.
United Kingdom, London
King's College London
United Kingdom, London
King's College Hospital
Bolodeoku, John
United Kingdom, Addlestone
Astellas Pharma Ltd
de Ridder, Dirk J.M.K.
Unknown Affiliation
Quackels, Thierry
Unknown Affiliation
de Leval, Jean
Unknown Affiliation
van Erps, Peter
Unknown Affiliation
Wadie, Bassem
Unknown Affiliation
Haab, François
Unknown Affiliation
Deval, Bruno
Unknown Affiliation
Amarenco, Gérard
Unknown Affiliation
Biserte, Jacques
Unknown Affiliation
Sofikitis, Nikolaos V.
Unknown Affiliation
Di Benedetto, Paolo
Unknown Affiliation
Pushkar, Dmitry Yu
Unknown Affiliation
Kliment, Ján
Unknown Affiliation
Castro-Díaz, David M.
Unknown Affiliation
Sánchez-Chapado, Manuel V.
Unknown Affiliation
Hetherington, John W.
Unknown Affiliation
Monga, Ash K.
Unknown Affiliation
Thakar, Ranee B.
Unknown Affiliation
Webb, Ralph J.
Unknown Affiliation
Statistics
Citations: 117
Authors: 21
Affiliations: 8
Identifiers
Doi:
10.1111/j.1464-410X.2008.07939.x
ISSN:
14644096
Research Areas
Disability
Health System And Policy